McDermott and Bull executive Search
 

Other News

Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026

Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol control with reduced treatment burden; repeat dosing in NHPs enabled further LDL-C lowering while maintaining tolerability STX-1200 surrogate achieved >95% Lp(a) reduction in non-human primates, without detectable off-target editing in primary human hepatocytes, reinforcing the potential for a potent and precise one-time Lp(a)-lowering therapy designed to recapitulate genetic protection of low Lp(a) Results reinforce Scribe’s approach to addressing a critical unmet need in cardiovascular care: ultra-long-acting therapies designed to sustainably and substantially lower atherogenic lipoproteins and empower patients to prevent disease before it develops ALAMEDA, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) — Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, reported updated preclinical data from its STX-1150 and STX-1200 programs at the American Heart Association (AHA) Scientific Sessions 2026. The findings bolster Scribe’s strategy to develop ultra-long-acting genetic medicines targeting key lipid drivers of atherosclerotic cardiovascular disease (ASCVD). Cardiovascular risk accumulates over decades of exposure to elevated atherogenic lipids, making early and sustained lipid lowering critical. The efficacy of existing LDL-C-lowering therapies depends on lifelong treatment persistence, but 50 to 70% of patients discontinue certain therapies within one year. Meanwhile, about one in five people have genetically elevated Lp(a), an independent and causal ASCVD risk factor with no approved therapies. Scribe’s STX-1150 and STX-1200 programs aim to address these challenges by translating the protective effects of naturally occurring human genetic variants into durable genetic medicines. “We believe that a majority of heart attacks could be prevented if patients and providers were able to proactively, easily, and sustainably reduce lipids that drive ASCVD,” said Benjamin L. Oakes, Ph.D., co-founder and CEO of Scribe Therapeutics. “Our AHA data reinforce the potential for purpose-built CRISPR medicines to transform chronic cholesterol management and bring us closer to our vision of making the protective benefits of human genetics accessible to millions of patients.” STX-1150: Epigenetic silencer sustains >50% LDL-C lowering for at least two years after a single therapeutically relevant dose STX-1150 is Scribe’s lead investigational CRISPR-based epigenetic silencing therapy, currently being evaluated in a first-in-human trial in adults with elevated LDL-C and increased cardiovascular risk. Utilizing Scribe’s proprietary Epigenetic Long-term X-Repressor (ELXR) technology, STX-1150 is designed to recapitulate the cardioprotective biology of individuals with naturally occurring PCSK9 loss-of-function variants by durably repressing PCSK9 transcription without cutting or permanently altering DNA. In a late-breaking presentation at AHA, Scribe reported that: A single administration of a STX-1150 prototype achieved up to 68% LDL-C reductions in non-human primates (NHPs), with >50% lowering sustained for two years at a therapeutically relevant dose.No off-target changes were detected and a GLP toxicology study identified no test-article-related adverse findings.STX-1150 showed ≥2 to 5-fold greater potency in human translational models compared to NHPs, supporting the potential for effective translation.In an additional NHP study, re-dosing of STX-1150 enabled progressively greater LDL-C lowering while maintaining tolerability. The findings demonstrate the potential for years of sustained LDL-C lowering from a single treatment with substantially reduced dosing burden compared with current therapies, while supporting the potential for repeat dosing. As previously announced, Scribe anticipates reporting initial clinical data from the single ascending dose portion of its Phase 1 trial of STX-1150 in the first half of 2027. STX-1200: Gene editor achieves saturating liver editing and >95% Lp(a) reduction in non-human primates with a single administration STX-1200 is an investigational CRISPR-CasX gene editing therapy designed to inactivate the LPA gene in hepatocytes through a single administration to durably lower circulating Lp(a). By reducing production of apolipoprotein(a) [Apo(a)], a key component of Lp(a), STX-1200 aims to recapitulate the protective biology of naturally occurring LPA-lowering variants. At AHA 2026, Scribe presented preclinical data demonstrating: A single administration of a STX-1200 surrogate achieved >80% hepatic LPA editing, associated with >95% reduction in circulating plasma Apo(a) at 10 weeks post-dose.A STX-1200 prototype achieved >95% serum Apo(a) reduction from a single low dose (125 nominated sites in primary human hepatocytes (PHHs), even at supersaturating doses. Taken together, the data support the potential for potent and precise Lp(a) lowering from a one-time treatment that aims to recapitulate the genetic protection of LPA-lowering variants. Continued development of STX-1200 is supported by a grant from the California Institute for Regenerative Medicine (CIRM). About Scribe Therapeutics Inc. Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The Company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding Scribe’s strategy, business plans and objectives; the therapeutic potential, safety, efficacy, durability, scalability and clinical or commercial prospects of Scribe’s product candidates and technologies; the design, initiation, enrollment, conduct, timing and results of preclinical studies and clinical trials; the timing of clinical data and other anticipated milestones; the advancement of STX-1150, STX-1200, and other programs; the potential for translation of STX-1150’s preclinical potency findings to humans and the potential for repeat dosing; and the expected use and benefits of CIRM funding are forward-looking statements. The words “aim,” “anticipate,” “believe,” “continue,” “could,” “design,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “target,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the risk that results of preclinical studies may not be predictive of results in clinical trials; the risk that the durability, potency and tolerability observed in preclinical models may not translate to humans; the risk that Scribe’s product candidates may cause undesirable side effects; and those described under the heading “Risk Factors” in Scribe’s filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026, and future reports that Scribe may file with the SEC. Except as required by law, Scribe undertakes no obligation to update any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events. Investor Contact:Investor Relations, Scribe Therapeuticsir@scribetx.com Media Contact:Thermal for Scribe Therapeuticsmedia@scribetx.com

AccurKardia Named a Rising Star Winner at the 2026 Digital Health Hub – Digital Health & AI Awards at HLTH USA

NEW YORK–(BUSINESS WIRE)– #Awards–AccurKardia, an ECG-led diagnostics software company, today announced that it has been named a winner at the 2026 Digital Health & AI Awards, presented by the Digital Health Hub Foundation at HLTH USA 2026 in Las Vegas. AccurKardia is one of three Rising Star winners in the Cardiometabolic, Obesity & Diabetes category. The Foundation selected 38 winners from more than 1,300 participating companies worldwide and announced them on November 16 at its Awards Grand

Conavi Medical Announces Five-Year Extension of Credit Facilities with Japan Lifeline

Extension to April 2032 enhances financial flexibility as Conavi advances U.S. commercialization of OCTIV™TORONTO, Nov. 18, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has entered into an amendment with Japan Lifeline Co., Ltd. (“Japan Lifeline”) extending the maturity of the Company’s existing senior secured credit facilities by five years, from April 2027 to April 2032. The extension better aligns Conavi’s debt maturity profile with its commercial development plans following FDA 510(k) clearance and the completion of its first U.S. commercial placement and clinical cases with the OCTIV™ hybrid imaging system. “Japan Lifeline has supported Conavi for more than a decade, and we appreciate its continued commitment as we advance commercialization,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “This extension gives us greater financial flexibility to build on our initial U.S. clinical and commercial milestones. Our focus is on expanding hospital placements, supporting physician adoption and generating additional clinical evidence demonstrating the value of hybrid imaging in coronary interventions.” The interest rate under the credit facilities will increase from 6.5% to 10% per annum; however, consistent with the existing terms of the credit facilities, Conavi is generally not required to make any interest payments until maturity.   Additional details regarding the amendment will be included in the Company’s regulatory filings on SEDAR+ at www.sedarplus.ca. About Conavi Medical Conavi Medical Corp. is a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures. Its OCTIV™ hybrid imaging system combines intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) to provide simultaneous, co-registered images of coronary arteries using a single imaging catheter. These complementary imaging modalities provide physicians with information to support treatment decisions during coronary interventions. For more information, visit www.conavi.com. Forward looking information This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging, the ability of Conavi’s hybrid imaging system to meet market needs and Conavi’s plans for expanding hospital placements, supporting physician adoption and generating additional clinical evidence. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contact Mark Quick, Chief Financial Officer | 416-483-0100Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com

InspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD’s CGuard Prime Carotid Stent Platform

Participating KOLs include six leading physician experts representing vascular surgery, interventional cardiology, vascular medicine, and neurosurgery Webinar to take place on Thursday, November 19, 2026 at 4:30 p.m. EST MIAMI, Nov. 17, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the Company will host a Key Opinion Leader (“KOL”) webinar, “The Next Chapter in Carotid Stenting: Six Physician Experts Discuss NSPR’s Innovative Technology,” on Thursday, November 19, 2026 at 4:30 p.m. EST. The webinar will feature six leading physician experts representing vascular surgery, interventional cardiology, vascular medicine, and neurosurgery, who will discuss carotid artery disease management and the advantages of InspireMD’s unique dual-layer mesh-covered stent technology. InspireMD’s CGuard Prime Carotid Stent platform is the only carotid stenting system that utilizes MicroNet™, a flexible, small-pore PET outer layer mesh that has demonstrated strong clinical results in preventing stroke during and after carotid revascularization procedures. The CGuard® Prime TransCarotid Stent System was approved by the U.S. Food and Drug Administration (“FDA”) on November 9, 2026 for use in transcarotid artery revascularization (“TCAR”) procedures. This follows FDA approval in June 2025 of the CGuard Prime system for use in transfemoral carotid artery stenting (“CAS”) procedures. TCAR and CAS are the two primary methods for carotid stenting, and the Company estimates that they combine to make up approximately 75,000 procedures in the U.S. annually. Featured Key Opinion Leaders include: Patrick Geraghty, MD, Professor of Surgery and Radiology, Section of Vascular Surgery, Washington University School of MedicinePatrick Muck, MD, Vascular Fellowship Program Director and Chief of Vascular Surgery, TriHealth Good Samaritan HospitalPeter Soukas, MD, Director, Peripheral Vascular Interventional Laboratory and Director of the Vascular & Endovascular Medicine Fellowship Program at Brown Health UniversityAdnan Siddiqui, MD, PhD, Vice-Chairman and Professor of Neurosurgery, Department of Neurosurgery (UBNS) at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical SciencesDimitrios Koudoumas, MD, PhD, Vascular Surgeon at Benefits Health SystemChris Metzger, MD, Director of the Diagnostic Catheterization and Interventional Labs at Ballad Health A live question-and-answer session will follow the formal presentation. Interested parties may register for the webinar here. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD’s or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. In particular, forward-looking statements in this press release include the Company’s estimates regarding the number of carotid stenting procedures performed annually in the United States and the potential market opportunity for the Company’s products. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the Company’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s need to raise additional capital to meet its business requirements in the future, and such capital raising may be costly or difficult to obtain and could dilute its stockholders’ ownership interests; the clinical development, commercialization and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; any impact of a product recall, including the voluntary recall in the U.S. of the CGuard Prime 135 cm Carotid Stent System, or any future product recall, on the Company’s business, results of operations and financial condition; negative clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in resuming U.S. commercialization of CGuard Prime following the voluntary recall or in the commercial launch of its other products; the Company’s dependence on a single manufacturing facility and its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than the Company does; entry of new competitors and products and potential technological obsolescence of the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation in the United States, Europe, Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign jurisdictions, exposing it to foreign currency exchange-rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws, and political and economic instability in each jurisdiction; security, political and economic instability in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on the Company, its customers and suppliers, and the global economic environment. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. Investor Contacts:Jeff WarrenLifeSci Advisorsjwarren@lifesciadvisors.cominvestor-relations@inspiremd.com

SOFIA™ Plus Aspiration Catheter

Terumo Neuro Announces Publication of RESTORE Registry Results in the Journal of NeuroInterventional Surgery

SOFIA™ Plus Aspiration Catheter

SOFIA™ Plus Aspiration Catheter

Aliso Viejo, CA, Nov. 17, 2026 (GLOBE NEWSWIRE) — Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced the publication of results from the RESTORE (REal-World Analyses of Stroke-Thrombus Occlusion REtrieval) registry in the Journal of NeuroInterventional Surgery (JNIS).    RESTORE was a prospective observational registry designed to describe procedural, functional, imaging, and safety outcomes associated with physician-directed mechanical thrombectomy procedures in real-world clinical practice. Devices used as first-line treatment in the observed procedures included the SOFIA™ family of catheters*, and the ERIC™ Retrieval Device, alone or in combination.   Reported RESTORE Outcomes  Among the 688 patients included in the published analysis, the authors reported:  93.0% final successful reperfusion, defined as a modified Thrombolysis in Cerebral Infarction score of mTICI ≥2b.  75.4% first-line reperfusion, defined as mTICI ≥2b.  60.8% first-pass successful reperfusion defined as mTICI ≥2b.  52.9% of patients included in the 90-day mRS analysis achieved functional independence, defined as a modified Rankin Scale (mRS) score ≤2.  55.7% of patients with premorbid mRS 0–2 achieved mRS ≤2 at 90 days.  0.6% symptomatic intracranial hemorrhage within 24 hours.  0.4% embolization to new territory.  3.5% device-related serious adverse events.  The publication also reports a median time of 13 minutes from puncture to clot contact and 17 minutes from puncture to successful reperfusion.  Successful navigation was reported in 97.4% of cases.  Angiographic outcomes were independently assessed by a Core Laboratory, and safety outcomes were reviewed and adjudicated by a Clinical Events Committee.  Final reperfusion may reflect additional passes and/or adjunctive or rescue therapy after first-line device use. The publication notes that device-specific crossover or rescue-device data were not available with sufficient granularity to attribute final reperfusion solely to the first-line device.   The full RESTORE study results are available in the Journal of NeuroInterventional Surgery: https://doi.org/10.1136/jnis-2026-025721  Treatment and device-selection decisions were made by treating physicians as part of routine clinical practice and were not assigned by the study protocol. The registry collected data from those procedures for research purposes. The registry enrolled 710 patients between June 2022 and December 2024. Device utilization is reported in the publication.  Because device use was physician-directed and the registry did not include a randomized or concurrent comparator, these outcomes should not be attributed to any individual device or interpreted as establishing comparative safety or effectiveness.   Study Design and Interpretation  RESTORE was a prospective, multicenter, observational, single-arm registry. Treatment windows, device selection, and procedural strategy were determined by the treating physician according to local standards of care.  RESTORE was an observational registry without randomization or a concurrent comparator arm. Its findings describe observed outcomes and do not establish comparative effectiveness or superiority over other devices or treatment strategies. Participating centers were predominantly high-volume stroke programs with established thrombectomy expertise, which should be considered when interpreting the results.  For More Information  Rebecca Janzon Director, Global Corporate Communications Terumo Neuro Email: Rebecca.janzon@microvention.com  About Terumo Neuro Terumo Neuro is on a mission to preserve and restore brain health by advancing innovation that changes what’s possible in neurovascular care. Working shoulder to shoulder with physicians, customers, and associates, we turn deep clinical insight into proven, refined solutions that elevate practice and improve patient outcomes — the kind of impact that redefines neuro-endovascular treatment. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers a comprehensive portfolio for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in Aliso Viejo, California, our products are sold in more than 70 countries.  For more information, please visit www.terumoneuro.com.  About Terumo Corporation  Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients and driven by the passion of its associates, Terumo strives to fulfill its Group Mission of “Contributing to Society through Healthcare.” Founded in Tokyo in 1921, Terumo provides a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.  INDICATIONS FOR USE / INTENDED PURPOSE:  *Device Use Reported in the Registry and U.S. Regulatory Status: The SOFIA 5F catheter is cleared in the United States for general intravascular use, including the neuro and peripheral vasculature, and is not indicated as an aspiration catheter. Its use in the registry reflected physician-directed treatment in real-world clinical practice. RESTORE did not assign or direct use of the SOFIA 5F catheter for aspiration and was not designed to establish its safety or effectiveness for that use.  The SOFIA™ Plus Aspiration Catheter (6F) (K173200) with the Gomco 405 Aspiration Pump and MicroVention Tubing Kit is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.   The SOFIA™ Distal Access Catheter (5F) (K142014, K131482) is intended for general intravascular use, including the neuro and peripheral vasculature. It can be used to facilitate the introduction of diagnostic and therapeutic agents. It is not intended for use in coronary arteries.   The ERIC™ Retrieval Device (K211120) is indicated to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.   For Healthcare Professional and Intended Uses Only.  Rx Only: Federal (USA) law restricts this device to sale by or on the order of a physician.  SOFIA™ and ERIC™ are trademarks of MicroVention, Inc., Terumo Neuro registered in the United States and other jurisdictions. All brand names and trademarks are registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties.  Refer to Instructions for Use, contraindications, and warnings for additional information.  © 2026 MicroVention, Inc. MM2518 EMEA-US 11/26  Contact Info Rebecca Janzonrebecca.janzon@microvention.com+1 949-685-4391 Attachment SOFIA™ Plus Aspiration Catheter

Perfuze Receives FDA Clearance for NeuroSheath™ 8F Long Sheath, Completing Its Stroke Thrombectomy System

GALWAY, Ireland–(BUSINESS WIRE)–Perfuze, a neurovascular medical device company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for NeuroSheath™, an 8 French (8F) long sheath specifically designed for neurovascular access. NeuroSheath completes Perfuze’s stroke thrombectomy system, from access through aspiration. It is sized to accommodate Millipede88®, the company’s super-bore aspiration catheter built on patented Corrugated™ technology. NeuroSheath will begin a lim